Prostate Cancer Treatment Pluvicto Currently in Shortage
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
The decision to withdraw the indication was made based on findings from the subsequent confirmatory phase 3 IMvigor130 trial.
Vegzelma is a vascular endothelial growth factor inhibitor.
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
The approval was based on data from the phase 3 ARASENS trial.
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
The Biologics License Application (BLA) for Vicineum included preliminary findings from the phase 3 VISTA trial.
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.